Prognostic Value of Blood-Based P-Tau217 Levels for Progression to Cognitive Impairment.

Buckley RF, Townsend DL, Birkenbihl CJ, Cuppels M, Coughlan GT, Seto MT, Brown JA, Properzi MJ, Hönig MC, Li A, Schultz AP, Chhatwal J, Yang HS, Arnold S, Kivisäkk P, James BD, O'Bryant S, Rissman RA, Petersen M, Caldwell JZK, Betthauser T, Oomens JE, Carrigan M, Healy B, Condado JG, Johnson SC, Yau WW, Langford O, Farrell M, Amariglio RE, Rentz DM, Papp KV, Brookmeyer R, Hohman TJ, Donohue M, Aisen PS, Johnson KA, Sperling RA, Alzheimer’s Disease Neuroimaging Initiative, Anti-Amyloid Treatment in Asymptomatic Alzheimer’s (A4) and Longitudinal Evaluation of Amyloid Risk and Neurodegeneration (LEARN) studies, Harvard Aging Brain Study (HABS), Health & Aging Brain Study – Health D, Alzheimer’s Disease Neuroimaging Initiative, Anti-Amyloid Treatment in Asymptomatic Alzheimer’s (A4) and Longitudinal Evaluation of Amyloid Risk and Neurodegeneration (LEARN) studies, Harvard Aging Brain Study (HABS), Health & Aging Brain Study – Health Disparities (HABS-HD), and Wisconsin Registry for Alzheimer’s Prevention (WRAP)

Open source

DOI: 10.1001/jama.2026.12556
Published: 2026 Sep 15
Container: JAMA
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1001/jama.2026.12556,
  title = {Prognostic Value of Blood-Based P-Tau217 Levels for Progression to Cognitive Impairment.},
  author = {Buckley RF and Townsend DL and Birkenbihl CJ and Cuppels M and Coughlan GT and Seto MT and Brown JA and Properzi MJ and Hönig MC and Li A and Schultz AP and Chhatwal J and Yang HS and Arnold S and Kivisäkk P and James BD and O'Bryant S and Rissman RA and Petersen M and Caldwell JZK and Betthauser T and Oomens JE and Carrigan M and Healy B and Condado JG and Johnson SC and Yau WW and Langford O and Farrell M and Amariglio RE and Rentz DM and Papp KV and Brookmeyer R and Hohman TJ and Donohue M and Aisen PS and Johnson KA and Sperling RA and Alzheimer’s Disease Neuroimaging Initiative, Anti-Amyloid Treatment in Asymptomatic Alzheimer’s (A4) and Longitudinal Evaluation of Amyloid Risk and Neurodegeneration (LEARN) studies, Harvard Aging Brain Study (HABS), Health \& Aging Brain Study – Health D and Alzheimer’s Disease Neuroimaging Initiative, Anti-Amyloid Treatment in Asymptomatic Alzheimer’s (A4) and Longitudinal Evaluation of Amyloid Risk and Neurodegeneration (LEARN) studies, Harvard Aging Brain Study (HABS), Health \& Aging Brain Study – Health Disparities (HABS-HD), and Wisconsin Registry for Alzheimer’s Prevention (WRAP)},
  year = {2026},
  journal = {JAMA},
  doi = {10.1001/jama.2026.12556},
  url = {https://doi.org/10.1001/jama.2026.12556}
}

RIS

TY  - JOUR
TI  - Prognostic Value of Blood-Based P-Tau217 Levels for Progression to Cognitive Impairment.
AU  - Buckley RF
AU  - Townsend DL
AU  - Birkenbihl CJ
AU  - Cuppels M
AU  - Coughlan GT
AU  - Seto MT
AU  - Brown JA
AU  - Properzi MJ
AU  - Hönig MC
AU  - Li A
AU  - Schultz AP
AU  - Chhatwal J
AU  - Yang HS
AU  - Arnold S
AU  - Kivisäkk P
AU  - James BD
AU  - O'Bryant S
AU  - Rissman RA
AU  - Petersen M
AU  - Caldwell JZK
AU  - Betthauser T
AU  - Oomens JE
AU  - Carrigan M
AU  - Healy B
AU  - Condado JG
AU  - Johnson SC
AU  - Yau WW
AU  - Langford O
AU  - Farrell M
AU  - Amariglio RE
AU  - Rentz DM
AU  - Papp KV
AU  - Brookmeyer R
AU  - Hohman TJ
AU  - Donohue M
AU  - Aisen PS
AU  - Johnson KA
AU  - Sperling RA
AU  - Alzheimer’s Disease Neuroimaging Initiative, Anti-Amyloid Treatment in Asymptomatic Alzheimer’s (A4) and Longitudinal Evaluation of Amyloid Risk and Neurodegeneration (LEARN) studies, Harvard Aging Brain Study (HABS), Health & Aging Brain Study – Health D
AU  - Alzheimer’s Disease Neuroimaging Initiative, Anti-Amyloid Treatment in Asymptomatic Alzheimer’s (A4) and Longitudinal Evaluation of Amyloid Risk and Neurodegeneration (LEARN) studies, Harvard Aging Brain Study (HABS), Health & Aging Brain Study – Health Disparities (HABS-HD), and Wisconsin Registry for Alzheimer’s Prevention (WRAP)
PY  - 2026
JO  - JAMA
DO  - 10.1001/jama.2026.12556
UR  - https://doi.org/10.1001/jama.2026.12556
ER  -

APA

RF, B., DL, T., CJ, B., M, C., GT, C., MT, S., JA, B., MJ, P., MC, H., A, L., AP, S., J, C., HS, Y., S, A., P, K., BD, J., S, O., RA, R., M, P., JZK, C., T, B., JE, O., M, C., B, H., JG, C., SC, J., WW, Y., O, L., M, F., RE, A., DM, R., KV, P., R, B., TJ, H., M, D., PS, A., KA, J., RA, S., D, A. D. N. I. A. T. I. A. A. (. A. L. E. O. A. R. A. N. (. S. H. A. B. S. (. H. &. A. B. S. –. H., & (WRAP), A. D. N. I. A. T. I. A. A. (. A. L. E. O. A. R. A. N. (. S. H. A. B. S. (. H. &. A. B. S. –. H. D. (. A. W. R. F. A. P. (2026). Prognostic Value of Blood-Based P-Tau217 Levels for Progression to Cognitive Impairment.. JAMA. https://doi.org/10.1001/jama.2026.12556

Source records

pubmed · retrieved 2026-09-25T12:52:13.144Z